

# CaixaResearch



## *CaixaResearch Validate form*

*Validate*

*2022*



"la Caixa" Foundation

## General Data and proposal information

### Application details

Call name:

Application number:

Proposal Title: **150 characters, mandatory.**

Proposal Description: **200 characters, mandatory.**

Proposal Acronym: **20 characters, mandatory.**

Project Leader:

Host Organization:

Faculty or Research Center (if applicable): **100 characters, optional.**

### Classification of the application

If \* is shown, the answers to that question are locked from modification when changing status from Pre-draft to Draft. User must return to Pre-draft status to modify these fields.

Select the business area of your project, **mandatory.**

	Therapeutics
	Diagnostics
	Medical Devices
	Digital Health

Select the scientific area(s) of your project, **mandatory.**

	Molecular and Structural Biology and Biochemistry
	Genetics, Genomics, Bioinformatics and Systems Biology
	Cellular and Developmental Biology
	Physiology, Pathophysiology and Endocrinology
	Neurosciences and Neural Disorders
	Immunity and Infection
	Diagnostic Tools, Therapies and Public Health
	Applied life Sciences and Non-Medical Biotechnology

Select the relevant subareas of your project, **mandatory.**

<b>1</b>	<b>Molecular and Structural Biology and Biochemistry</b>
1_1	Molecular interactions
1_2	General biochemistry and metabolism
1_3	DNA synthesis, modification, repair, recombination and degradation
1_4	RNA synthesis, processing, modification and degradation
1_5	Protein synthesis, modification and turnover
1_6	Lipid synthesis, modification and turnover
1_7	Carbohydrate synthesis, modification and turnover
1_8	Biophysics (e.g. transport mechanisms, bioenergetics, fluorescence)
1_9	Structural biology (crystallography and EM)
1_10	Structural biology (NMR)
1_11	Biochemistry and molecular mechanisms of signal transduction

<b>2</b>	<b>Genetics, Genomics, Bioinformatics and Systems Biology</b>
2_1	Genomics, comparative genomics, functional genomics
2_2	Transcriptomics
2_3	Proteomics
2_4	Metabolomics
2_5	Glycomics
2_6	Molecular genetics, reverse genetics and RNAi
2_7	Quantitative genetics
2_8	Epigenetics and gene regulation
2_9	Genetic epidemiology
2_10	Bioinformatics
2_11	Computational biology
2_12	Biostatistics
2_13	Systems biology
2_14	Biological systems analysis, modelling and simulation
<b>3</b>	<b>Cellular and Developmental Biology</b>
3_1	Morphology and functional imaging of cells
3_2	Cell biology and molecular transport mechanisms
3_3	Cell cycle and division
3_4	Apoptosis
3_5	Cell differentiation, physiology and dynamics
3_6	Organelle biology
3_7	Cell signalling and cellular interactions
3_8	Signal transduction
3_9	Development, developmental genetics, pattern formation and embryology
3_10	Cell genetics
3_11	Stem cell biology
3_12	Morphology and functional imaging of cells
<b>4</b>	<b>Physiology, Pathophysiology and Endocrinology</b>
4_1	Organ physiology and pathophysiology
4_3	Endocrinology
4_4	Ageing
4_5	Metabolism, biological basis of metabolism related disorders
4_6	Cancer and its biological basis
4_7	Cardiovascular diseases
4_8	Non-communicable diseases (except for neural/psychiatric, immunity-related, metabolism-related disorders, cancer and cardiovascular diseases)
<b>5</b>	<b>Neurosciences and Neural Disorders</b>
5_1	Neuroanatomy and neurophysiology
5_2	Molecular and cellular neuroscience
5_3	Neurochemistry and neuropharmacology
5_4	Sensory systems (e.g. visual system, auditory system)
5_5	Mechanisms of pain
5_6	Developmental neurobiology
5_7	Cognition (e.g. learning, memory, emotions, speech)
5_8	Behavioural neuroscience (e.g. sleep, consciousness, handedness)
5_9	Systems neuroscience
5_10	Neuroimaging and computational neuroscience

5_11	Neurological disorders (e.g. Alzheimer's disease, Huntington's disease, Parkinson's disease)
5_12	Psychiatric disorders (e.g. schizophrenia, autism, Tourette's syndrome, obsessive compulsive disorder, depression, bipolar disorder, attention deficit hyperactivity disorder)
<b>6</b>	<b>Immunity and Infection</b>
6_1	Innate immunity and inflammation
6_2	Adaptive immunity
6_3	Phagocytosis and cellular immunity
6_4	Immunosignalling
6_5	Immunological memory and tolerance
6_6	Immunogenetics
6_7	Microbiology
6_8	Virology
6_9	Bacteriology
6_10	Parasitology
6_11	Prevention and treatment of infection by pathogens (e.g. vaccination, antibiotics, fungicide)
6_12	Biological basis of immunity related disorders (e.g. autoimmunity)
<b>7</b>	<b>Diagnostic Tools, Therapies and Public Health</b>
7_1	Medical engineering and technology
7_2	Diagnostic tools (e.g. genetic, imaging)
7_3	Pharmacology, pharmacogenomics, drug discovery and design, drug therapy
7_4	Analgesia and Surgery
7_5	Toxicology
7_6	Gene therapy, cell therapy, regenerative medicine
7_7	Radiation therapy
7_8	Health services, health care research
7_9	Public health and epidemiology
7_10	Environment and health risks, occupational medicine
7_11	Medical ethics
<b>8</b>	<b>Applied life Sciences and Non-Medical Biotechnology</b>
8_1	Applied genetic engineering, transgenic organisms, recombinant proteins, biosensors
8_2	Synthetic biology, chemical biology and new bio-engineering concepts
8_3	Food sciences

Select the type of your proposal, [mandatory](#).

Individual proposal
Consortium

*If user selects Consortium, the section "Consortium" must be visible in the form.*

Classify your proposal, [mandatory](#).

Proposal without Co-Owner(s) of Asset/s
Proposal with Co-Owner(s) of Asset/s

*If user selects Proposal with Co-Owner(s) of Asset/s, then "Co-Owner of Asset/s details" is shown.*

Select the option that best suits your proposal, **mandatory**.

Cardiovascular
Experimental and mathematical sciences
Infectious diseases
Medical sciences
Neurosciences
Oncology
Other health sciences

**Information for “la Caixa” Foundation**

*This information will be only used for monitoring/statistical purposes.*

Are you or any member of your group applying to any other “la Caixa” call (research, innovation projects and fellowships, **mandatory**).

Yes
No

Please indicate the application code (such as HR20-00001, CI19-00001...) for each of the proposals where you or a member of your group apply:

#	Application code
1	HR21-00001
2	CI21-00001
3	CC21-10001

Do you or any member of your group have an ongoing project with “la Caixa” (research, innovation projects and fellowships)? **mandatory**.

Yes
No

Please indicate the project code (such as LCF/PR/HR17/52150017) for each of the proposals where you or a member of your group apply:

#	Application code
1	LCF/PR/HR17/52150017

**Proposal Information**

**Scientific Abstract (proposal summary)**

The abstract must provide a brief description of the project, the specific objectives and the values that it brings to its scientific field and society. 2000 characters. Mandatory.

### Five most important scientific publications

Up to 5 references. Optional.

#	DOI	Title of the document	Authors	Journal	Year

### Level of development of the Asset/s

Brief description and level of development of the Asset/s  
1500 characters. Mandatory.

*Description of the technology status. Has the hypothesis been tested?*

*Has the Asset/s undergone experimental proof-of-concept?*

*Has the Asset/s been validated in real conditions?*

### Technology Readiness Level

Please indicate the [Technology Readiness level](#).

Mandatory.

	1
	2
	3
	4
	5
	6
	7
	8
	9

### Protection status of the Asset/s to be valued

Please indicate the Protection status of the Asset/s.

Mandatory.

	Patent/utility model not filed
	Patent pending
	Utility model pending
	Patent granted
	Utility model granted
	Trademark
	Industrial design right
	Trade Secret

## Project description

### Need or problem to be solved

Description of the reasons behind the development of the Asset/s. Describe the unmet need or problem it addresses and the foreseen impact after the implementation of the technology.

2500 characters. Mandatory.

### Value proposition

Describe whether the product represents an absolute novelty or if other solutions for solving the product already exist in the market or are being developed. Identification and description of consequences of transferring the Asset/s to society.

**1500 characters. Mandatory.**

*Value proposition is the contribution of the Asset/s to improving people's quality of life, societal progress and/or human development.*

### Valorisation actions

Valorisation actions developed and results to date, valorisation actions estimated to be developed within the programme and indicative cost according to table provided under "Budget" section. All the actions should be linked to specific project objectives.

**2500 characters. Mandatory.**

*Valorisation is the process of value-creation out of knowledge, by making this knowledge suitable and available for economic or societal utilisation and to translate this into high-potential products, services, processes and industrial activity. Therefore, explain which activities – scientific, business, IP, regulatory, market...- will be carried out to turn the project into Asset/s for society within the programme framework. Estimate the plan and the resources needed to its implementation-*

### Work Plan (Gantt Chart)

Please indicate the proposal workplan in a Gantt Diagram. Use the + button below to add Tasks. They will be displayed in the Gantt Chart below, after doing save draft.

## Project analysis

### Market to be addressed and clients

Identification and quantitative estimation of potential direct and indirect beneficiaries of the solution. Identification of the client or potential clients. Estimation of the potential market size (national, international...) and economic impact.

**2500 characters. Mandatory.**

### Initial identification and involvement of different stakeholders

Which people or groups of people are critical for the success of the project and could therefore have a positive or negative effect on the transfer to the market?

How the project addresses Responsible Research and Innovation dimensions such gender balance, ethical aspects, patient engagement.

**1500 characters. Mandatory.**

Project Team

## Partners of the Project

List up all Partners and COA of your project

Organization	Country	Name (PL/Partner/COA)	Role
--------------	---------	-----------------------	------

## Project Leader and team

### Project leader's expertise and commitment

Describe the project leader capabilities that would contribute to the development and future transfer of the Asset/s. Describe the future involvement of the project leader in the development of the Asset/s. What are his/her expectations regarding the programme?  
1500 characters. Mandatory.

### Relevance and complementarity of team members and partners

Provide details of the profiles of team members and partners (if applies) and their dedication to the project. Describe how they are relevant and the complementarity of their profiles.  
2000 characters. Mandatory.

### Project team members' details (if relevant)

Scientific, technical and management profiles from the organizations involved in the development of project:

Prefix	Name and surname	Job title, centre	Profile, experience	Dedication to the project during the participation in CaixaImpulse
5 char.	100 char.	100 char.	1000 characters.	

Budget

Open:

[Button](#), opens new window in browser with the larger budget table. Mandatory.

Concept	Requested grant to "la Caixa" Foundation	Other contributions	Total Project Cost	Details
Materials for experiments / R&D	0.00	0.00	0.00	Text
Materials for experiments/ R&D	0.00	0.00	0.00	Text
Outsourcing of activities for R&D development	0.00	0.00	0.00	Text
Recruitment of personnel for the project	0.00	0.00	0.00	Text
Intellectual property protection	0.00	0.00	0.00	Text
Technical / scientific advice	0.00	0.00	0.00	Text
Business advice	0.00	0.00	0.00	Text
Legal advice	0.00	0.00	0.00	Text
Commercial and market analysis actions	0.00	0.00	0.00	Text
Regulatory development	0.00	0.00	0.00	Text
Production	0.00	0.00	0.00	Text
Design	0.00	0.00	0.00	Text
Prototyping	0.00	0.00	0.00	Text
Travel expenses related to Valorisation Plan	0.00	0.00	0.00	Text
Others	0.00	0.00	0.00	Text

Information from Partner Organizations that receive funding from the grant must be included in the corresponding table:

Partner Organization	TOTAL REQUESTED



## Documentation

### Complementary documentation for project evaluation

Patent or utility model application

**Optional. Only PDF.**

Letters of support or recommendation.

**Optional. Only PDF.**

Prototypes.

**Optional. Only PDF. PDFs must not surpass 1 page.**

FBLC reserves the right to ask the applicant for a translation of the documentation into English if in any case it is required.

